Physicians' Education Resource
Last Modified: June 1, 2008
Conference Dates: October 25, 2008
Conference Location: Dallas, TX
Sponsoring Group: Physicians' Education Resource
Conference Web Page URL: http://www.cancerconferences.com/multi_disease/nursephysician_symposium/index.php
Topics Covered: The Annual Symposium for Nurses and Pharmacists Specializing in Oncology: Assessing and Managing Side Effects in the Era of Targeted Therapies is intended to educate oncology nurses and pharmacists on the state-of-the-art options for effective management of cancer and treatment-related complications. The theme of this year’s meeting will focus on recognizing and managing targeted agent–related class effects, such as skin rash, hand-foot syndrome, fatigue, hypertension, bleeding events, and cardiotoxicity. Overviews of the rationale of specific targeted approaches, mechanisms of action, and toxicity will be followed by more detailed information on side effects and contemporary management paradigms. Case-based approaches dealing with specific clinical scenarios will provide the audience with up-to-date skills in assessing and managing newer targeted therapeutics and provide both a firm grasp of the underlying concepts and a basis for continued learning as the field evolves.
At the conclusion of this symposium, you should be able to: Assess and manage cutaneous complications related to agents targeting EGFR Assess and manage adverse events, including hypertension, bleeding, and wound-healing complications associated with angiogenesis inhibitors Discuss side effects, including fatigue and diarrhea, associated with the use of multitargeted tyrosine kinase inhibitors Assess practical issues in compliance with oral drug therapy Review the pathophysiology of the EGFR family in cancer and describe the in vivo mechanisms of action of EGFR-targeted agents Explain the rationale for targeting the tumor microenvironment in anticancer therapy and list the antiangiogenic agents under investigation Describe interactions of anticancer drugs with other drugs and common food substances and their impact on treatment outcomes Identify inherited and tumor genomic factors that affect toxicity and efficacy of cancer therapeutics Identify effective means to communicate with patients and families regarding such issues as treatment options, selection of clinical trials, symptom management, and end-of-life care Discuss the coordination of a multidisciplinary team based on patients’ response to targeted therapy
Registration Information: Registration fees include continental breakfast, lunch, and syllabus materials. INDUSTRY is defined by PER as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical. Industry registrations cannot be processed on-line. To request attendance at a Congress, registrations can be submitted via fax, phone or e-mail. For more information e-mail us at CME@pergrouplp.com. A cancellation fee of 25% will be assessed on refunds requested before September 11, 2008, and a 50% fee on requests made between September 11, 2008, and September 26, 2008. No refunds will be made after September 26, 2008. There is no charge for substitution. Persons who register within 2 weeks of the meeting might not receive conference materials.
Conference Fees: Nurses, Pharmacists, Fellows, PAs $40.00, Physicians $60.00, Industry* $250.00
Continuing Education: Yes, Nurses: Physicians’ Education Resource is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This activity meets Type I criteria for mandatory continuing education requirements toward relicensure as established by the Texas Board of Nursing. Pharmacists: Physicians’ Education Resource is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been approved for AMA PRA Category 1 Credit™.
Oct 4, 2011 - Treatment of localized prostate cancer using intensity modulated radiation therapy is associated with a considerable reduction in late bowel and rectal side effects and significantly decreased rectal and bladder toxicity compared to three-dimensional conformal radiation therapy, according to a study presented the annual meeting of the American Society for Radiation Oncology, held from Oct. 2 to 6 in Miami Beach.